Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT00004922
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced neuroendocrine tumors.

Key Dates

Start date
Jun 30, 1999
Status verified
Jun 2013
Primary completion
Jun 30, 2002
Completion
Jun 30, 2002

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in New York, NY

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Memorial Sloan-Kettering Cancer Center· New York, NY

Related Studies